The Role of JAK2 Abnormalities in Hematologic Neoplasms
Blood Diseases Center, King Fahad Hofuf Hospital, Hassa P.O. Box 1 31982, Saudi Arabia
Hematol. Rev. 2009, 1(1), e10; https://doi.org/10.4081/hr.2009.e10 (registering DOI)
Received: 3 May 2009
Revised: 3 June 2009
Accepted: 24 June 2009
Published: 9 July 2009
In 2005, an activating mutation in the Janus kinase 2 (JAK2) was identified in a significant proportion of patients with myeloproliferative neoplasms, mainly polycythemia vera, essential thrombocythemia and primary myelofibrosis. Many types of mutations in the JAK-STAT pathway have been identified, the majority are related to JAK2. Currently JAK2 mutations are important in the area of diagnosis of myeloid neoplasms, but its role beyond the confirmation of clonality is growing and widening our knowledge about these disorders. In addition to that, clinical trials to target JAK2-STAT pathway will widen our knowledge and hopefully will offer more therapeutic options. In this review, we will discuss the role of JAK2 abnormalities in the pathogenesis, diagnosis, classification, severity and management of hematologic neoplasms.
Share and Cite
MDPI and ACS Style
The Role of JAK2 Abnormalities in Hematologic Neoplasms. Hematol. Rev. 2009, 1, e10.
The Role of JAK2 Abnormalities in Hematologic Neoplasms. Hematology Reviews. 2009; 1(1):e10.
Alabdulaali, Mohammed K.
2009. "The Role of JAK2 Abnormalities in Hematologic Neoplasms" Hematology Reviews 1, no. 1: e10.
Article Access Statistics
Multiple requests from the same IP address are counted as one view.